Brief Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 7, 2012; 18(33): 4533-4541
Published online Sep 7, 2012. doi: 10.3748/wjg.v18.i33.4533
Table 3 Results of univariate and multivariate analysis for overall survival with FOLFIRI
DeathUnivariate analysisMultivariate analysis
Yes/no (49/14)HR95% CIP valueHR95% CIP value
Primary tumor location10.306
Body or tail16/21
Head25/70.717(0.380-1.355)
Stage at the diagnosis0.7540.644
Resectable20/411
Locally advanced13/61.012(0.497-2.058)0.790(0.346-1.806)
Metastatic16/41.271(0.643-2.515)1.205(0.577-2.514)
Previous surgery0.203
No31/91
Yes18/50.676(0.370-1.236)
Previous radiotherapy0.9160.935
No38/911
Yes11/50.964(0.491-1.894)0.965(0.412-2.260)
Number of previous chemotherapy lines0.1020.171
114/511
230/91.234(0.649-2.346)1.197(0.564-2.538)
35/03.188(1.090-9.326)2.945(0.930-9.324)
Liver metastases0.5990.957
No9/311
Yes40/111.217(0.586-2.528)0.978(0.444-2.159)
WHO performance status0.0040.004
022/511
118/61.360(0.719-2.573)1.284(0.650-2.535)
29/34.003(1.770-9.056)4.702(1.883-11.741)
Type of FOLFIRI regimen0.856
FOLFIRI-142/131
FOLFIRI-37/11.083(0.458-2.562)